Friday, December 15, 2017
From The Washington Post:
The Ensuring Patient Access and Effective Drug Enforcement Act of 2016 was pushed through Congress by a small band of lawmakers backed by a powerful array of drug companies. The law has undermined the DEA’s most potent tools in the war against the opioid epidemic, according to agency investigators, agents, lawyers and the DEA’s chief administrative law judge.
. . .
During a Senate Judiciary Committee hearing Tuesday, the head of the DEA office that regulates the pharmaceutical industry said the law has made enforcement more difficult in urgent circumstances and should be revised.